Platinum-resistant Ovarian Cancer Terminated Phase 2 / 3 Trials for Combretastatin (DB12596)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Terminated2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02641639FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerTreatment